Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11735334 | 0.87 | LMNA (0.77) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| Ronidazole SCHEMBL635714 | 0.86 | LMNA (1.00) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL13313842 | 0.84 | LMNA (0.73) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL15752503 | 0.82 | LMNA (0.68) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL7557867 | 0.81 | LMNA (0.64) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL31018738 | 0.80 | LMNA (0.67) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL31018740 | 0.80 | LMNA (0.67) | LMNACYP2C19GLAALDH1A1MAPK1 | |
| SCHEMBL11641368 | 0.80 | LMNA (0.67) | LMNACYP2C19GLAALDH1A1EGFR | |
| SCHEMBL11637096 | 0.79 | LMNA (0.65) | LMNACYP2C19ALDH1A1MAPK1NPC1 | |
| SCHEMBL31018737 | 0.78 | LMNA (0.63) | LMNACYP2C19GLAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080145372-A1 | Bioreductively-Activated Prodrugs | ANGIOGENE, PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145372-A1 | Bioreductively-Activated Prodrugs | NME2, PNP, NUDT1 | LMNA 1716/4885CYP2C19 35/4885GLA 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.